Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label …
EA Joura, A Ulied, C Vandermeulen, MR Figueroa… - Vaccine, 2021 - Elsevier
… vaccine also showed prevention against cervical intraepithelial neoplasia caused by HPV …
To understand the applicability of these efficacy findings to older women, we report data from …
To understand the applicability of these efficacy findings to older women, we report data from …
Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: a phase 3 open-label study
H Lv, S Wang, Z Liang, W Yu, C Yan, Y Chen, X Hu… - Vaccine, 2022 - Elsevier
… aged 16–26 years in 2018. … vaccine immunogenicity and safety in Chinese females aged
9–19 years and 27–45 years with Chinese females aged 20–26 years; we report results from …
9–19 years and 27–45 years with Chinese females aged 20–26 years; we report results from …
[PDF][PDF] 9-valent Human Papillomavirus Vaccine Provides Further Protection Against Anogenital Cancers and Genital Warts
ER Howe - elizabeth-howe.com
… cervical intraepithelial neoplasia 2 and 3 (CIN2 and CIN3), as well as cervical adenocarcinoma
in situ (>CIN2) are most often caused by HPV infection; 50% are caused by HPV types …
in situ (>CIN2) are most often caused by HPV infection; 50% are caused by HPV types …
Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety
J Restrepo, T Herrera, R Samakoses, JC Reina… - …, 2023 - publications.aap.org
… intraepithelial neoplasia or condyloma in males or females. Incidence rates of HPV6/11/16/18/31/33/45/52/58-related
6-month persistent infection in males and females … in vaccinated …
6-month persistent infection in males and females … in vaccinated …
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men
AR Giuliano, T Wilkin, OM Bautista, K Cheon… - Contemporary clinical …, 2022 - Elsevier
… Clinical trial results Human clinical trials have shown that prophylactic HPV vaccines based
on L1 VLPs are highly efficacious to prevent HPV infection and intraepithelial neoplasia …
on L1 VLPs are highly efficacious to prevent HPV infection and intraepithelial neoplasia …
Towards the elimination of cervical cancer: HPV epidemiology, real-world experiences and the potential impact of the 9-valent HPV vaccine
GM Prandi, S Cocchio, M Fonzo, P Furlan… - European Journal of …, 2021 - research.unipd.it
… events observed after HPV vaccine administration… infections with both vaccine and non-vaccine
HPV types or in the rates of cervical intraepithelial neoplasia and invasive cervical cancer…
HPV types or in the rates of cervical intraepithelial neoplasia and invasive cervical cancer…
[HTML][HTML] … immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of …
SE Olsson, JA Restrepo, JC Reina, P Pitisuttithum… - Papillomavirus …, 2020 - Elsevier
… -grade intraepithelial neoplasia or genital … infection in females and males were 49.2 and
37.3 per 10,000 person-years, respectively, which were within ranges expected in vaccinated …
37.3 per 10,000 person-years, respectively, which were within ranges expected in vaccinated …
… the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
AB Kind, A Pavelyev, S Kothari, N El Mouaddin… - BMC Public Health, 2020 - Springer
… benefits of a 9-valent vaccination compared with the current vaccination programme has
been … to a 9-valent HPV vaccination programme for 11–26 years old boys and girls from the …
been … to a 9-valent HPV vaccination programme for 11–26 years old boys and girls from the …
Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus–Vaccinated Women …
CM Domröse, U Wieland, H Pilch… - … Genital Tract Disease, 2022 - journals.lww.com
… vaccinated women despite established effectiveness of prophylactic human papillomavirus
(HPV) vaccination. … characteristics of women with CIN 3 after HPV vaccination referred to a …
(HPV) vaccination. … characteristics of women with CIN 3 after HPV vaccination referred to a …
[HTML][HTML] Safety of 9-valent human papillomavirus vaccine administered to males and females in routine use
J Hansen, A Yee, N Lewis, S Li, C Velicer, P Saddier… - Vaccine, 2023 - Elsevier
… Study of safety of 9-valent HPV vaccine in males and females ages 9 and up. … both males
and females, whereas earlier HPV vaccine safety studies were limited to only females [8], [28] …
and females, whereas earlier HPV vaccine safety studies were limited to only females [8], [28] …